ZOKINVY (lonafarnib)
PROGERIA SYNDROME TREATMENT AGENTS · HUTCHINSON-GILFORD PROGERIA SYNDROME ·+2
SENTYNL THERAPU
Drug class
Progeria Syndrome Treatment Agents
Progeria syndrome treatment agents are a specialized therapeutic category commonly utilized in drug formularies to classify therapies that target the molecular pathology of ultra-rare, fatal premature aging disorders. Read more about Progeria Syndrome Treatment Agents
1 drugs in this class 1 manufacturers
Drugs in Progeria Syndrome Treatment Agents
Filter & compare in the drug finder →
Opens the drug finder with Progeria Syndrome Treatment Agents preselected. Add indication or manufacturer filters there.
Progeria syndrome treatment agents are a specialized therapeutic category commonly utilized in drug formularies to classify therapies that target the molecular pathology of ultra-rare, fatal premature aging disorders.
Represented clinically by farnesyltransferase inhibitors such as lonafarnib, these agents function by blocking the post-translational farnesylation and subsequent accumulation of aberrant lamin proteins—specifically progerin—at the inner nuclear membrane, thereby preserving nuclear architecture and cellular integrity.
The primary disease indications for this class include reducing mortality and disease burden in Hutchinson-Gilford progeria syndrome and treating specific processing-deficient progeroid laminopathies.
-
communitycarehealth.org
Progeria syndrome treatment agents are a specialized therapeutic category commonly utilized in drug formularies to classify therapies that target the molecular pathology of ultra-rare, fatal premature aging disorders
-
delveinsight.com
Progeria syndrome treatment agents are a specialized therapeutic category commonly utilized in drug formularies to classify therapies that target the molecular pathology of ultra-rare, fatal premature aging disorders
-
nih.gov
Represented clinically by farnesyltransferase inhibitors such as lonafarnib, these agents function by blocking the post-translational farnesylation and subsequent accumulation of aberrant lamin proteins—specifically progerin—at the inner nuclear membrane, thereby preserving nuclear architecture and cellular integrity
-
pharmacompass.com
Represented clinically by farnesyltransferase inhibitors such as lonafarnib, these agents function by blocking the post-translational farnesylation and subsequent accumulation of aberrant lamin proteins—specifically progerin—at the inner nuclear membrane, thereby preserving nuclear architecture and cellular integrity The primary disease indications for this class include reducing mortality and disease burden in Hutchinson-Gilford progeria syndrome and treating specific processing-deficient proge...
-
selleckchem.com
Represented clinically by farnesyltransferase inhibitors such as lonafarnib, these agents function by blocking the post-translational farnesylation and subsequent accumulation of aberrant lamin proteins—specifically progerin—at the inner nuclear membrane, thereby preserving nuclear architecture and cellular integrity
-
fda.gov
The primary disease indications for this class include reducing mortality and disease burden in Hutchinson-Gilford progeria syndrome and treating specific processing-deficient progeroid laminopathies
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.